ifosfamide has been researched along with Lymphoma, T-Cell in 22 studies
Lymphoma, T-Cell: A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We performed a phase I study to determine the safety and maximum tolerated dose (MTD) of selinexor when combined with high-dose dexamethasone, ifosfamide, carboplatin and etoposide (DICE) in relapsed/refractory (R/R) T-cell lymphoma (TCL) and natural-killer/T-cell lymphoma (NKTL)." | 9.41 | Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma ( Chan, JY; Farid, M; Lim, C; Lim, ST; Martin, P; Poon, E; Somasundaram, N; Tang, T; Tao, M; Toh, SQ; Yan, SX; Yunon, MJ, 2021) |
| "This study evaluated the efficacy and safety of a new regimen consisting of Topotecan, Ifosfamide, Etoposide, and L-asparaginase (TIEL) in treating aggressive T-cell lymphoma." | 9.20 | Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma. ( Chen, S; Guan, M; Jia, N; Shao, Y; Wang, Y, 2015) |
| "Combination chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) was active as first-line and second-line treatment for extranodal natural killer/T-cell lymphoma (NTCL)." | 9.19 | A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group. ( Bae, SH; Chung, J; Heo, DS; Hyun, MS; Jeon, YK; Kang, YK; Kim, BS; Kim, CW; Kim, DW; Kim, H; Kim, HJ; Kim, TM; Lee, JS; Song, HS; Yang, SH; Yuh, YJ, 2014) |
| "To describe the clinical course of patients with angioimmunoblastic lymphadenopathy (AILD)-type lymphoma with a sequential treatment with prednisone and COPBLAM/IMVP-16." | 9.07 | Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. ( Agthe, A; Brittinger, G; Engelhard, M; Griesser, H; Huhn, D; Kuse, R; Lennert, K; Schwerdtfeger, R; Siegert, W; Tiemann, M, 1992) |
| "Contemporary data of peripheral T-cell lymphoma (PTCL) and natural-killer/T-cell lymphoma (NKTL) patients treated with ifosfamide, carboplatin and etoposide (ICE) are limited." | 8.12 | Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. ( Chan, EHL; Chan, JYS; Chang, EWY; Chee, YL; de Mel, S; Diong, C; Farid, M; Goh, AZK; Goh, YT; Grigoropoulos, NF; Jeyasekharan, A; Khoo, LP; Lee, J; Lee, YS; Lim, C; Lim, ST; Liu, X; Nagarajan, C; Poon, E; Poon, M; Quek, R; Somasundaram, N; Tan, D; Tang, T; Tao, M; Tay, T; Yang, VSW, 2022) |
| " We performed a phase I study to determine the safety and maximum tolerated dose (MTD) of selinexor when combined with high-dose dexamethasone, ifosfamide, carboplatin and etoposide (DICE) in relapsed/refractory (R/R) T-cell lymphoma (TCL) and natural-killer/T-cell lymphoma (NKTL)." | 5.41 | Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma ( Chan, JY; Farid, M; Lim, C; Lim, ST; Martin, P; Poon, E; Somasundaram, N; Tang, T; Tao, M; Toh, SQ; Yan, SX; Yunon, MJ, 2021) |
| "This study evaluated the efficacy and safety of a new regimen consisting of Topotecan, Ifosfamide, Etoposide, and L-asparaginase (TIEL) in treating aggressive T-cell lymphoma." | 5.20 | Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma. ( Chen, S; Guan, M; Jia, N; Shao, Y; Wang, Y, 2015) |
| "Combination chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) was active as first-line and second-line treatment for extranodal natural killer/T-cell lymphoma (NTCL)." | 5.19 | A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group. ( Bae, SH; Chung, J; Heo, DS; Hyun, MS; Jeon, YK; Kang, YK; Kim, BS; Kim, CW; Kim, DW; Kim, H; Kim, HJ; Kim, TM; Lee, JS; Song, HS; Yang, SH; Yuh, YJ, 2014) |
| "To describe the clinical course of patients with angioimmunoblastic lymphadenopathy (AILD)-type lymphoma with a sequential treatment with prednisone and COPBLAM/IMVP-16." | 5.07 | Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. ( Agthe, A; Brittinger, G; Engelhard, M; Griesser, H; Huhn, D; Kuse, R; Lennert, K; Schwerdtfeger, R; Siegert, W; Tiemann, M, 1992) |
| "Contemporary data of peripheral T-cell lymphoma (PTCL) and natural-killer/T-cell lymphoma (NKTL) patients treated with ifosfamide, carboplatin and etoposide (ICE) are limited." | 4.12 | Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy. ( Chan, EHL; Chan, JYS; Chang, EWY; Chee, YL; de Mel, S; Diong, C; Farid, M; Goh, AZK; Goh, YT; Grigoropoulos, NF; Jeyasekharan, A; Khoo, LP; Lee, J; Lee, YS; Lim, C; Lim, ST; Liu, X; Nagarajan, C; Poon, E; Poon, M; Quek, R; Somasundaram, N; Tan, D; Tang, T; Tao, M; Tay, T; Yang, VSW, 2022) |
| "The present study aimed to analyse the treatment outcome of IMVP-16/Pd (ifosfamide, methotrexate, etoposide and prednisone) followed by high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) for patients with peripheral T-cell lymphomas (PTCLs) who were previously treated with CHOP." | 3.73 | IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas. ( Im, YH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, WS; Ko, YH; Lee, J; Lee, MH; Lee, SH; Park, BB; Park, JO; Park, K; Park, KW; Park, YS, 2005) |
| "Therapy for group non-B patients (lymphoblastic lymphoma and pleomorphic T-cell lymphoma [PTCL]) consisted of a Berlin-Frankfurt-Münster (BFM) acute lymphoblastic leukemia protocol, including cranial irradiation for advanced stage." | 2.68 | Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. ( Gadner, H; Henze, G; Ludwig, WD; Müller-Weihrich, S; Parwaresch, R; Reiter, A; Riehm, H; Sauter, S; Schrappe, M; Sykora, KW, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 6 (27.27) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Tay, T | 1 |
| Somasundaram, N | 2 |
| Lim, C | 2 |
| Khoo, LP | 1 |
| Goh, AZK | 1 |
| Lee, YS | 1 |
| Liu, X | 1 |
| Tao, M | 3 |
| Quek, R | 2 |
| Farid, M | 3 |
| Poon, E | 2 |
| Chan, JYS | 1 |
| Chang, EWY | 1 |
| Yang, VSW | 1 |
| Goh, YT | 1 |
| Tan, D | 1 |
| Diong, C | 1 |
| Grigoropoulos, NF | 1 |
| Nagarajan, C | 1 |
| Poon, M | 1 |
| de Mel, S | 1 |
| Jeyasekharan, A | 1 |
| Chan, EHL | 1 |
| Lee, J | 2 |
| Chee, YL | 1 |
| Lim, ST | 3 |
| Tang, T | 2 |
| Nagahama, J | 1 |
| Nishikawa, T | 1 |
| Tasaki, T | 1 |
| Yasudome, Y | 1 |
| Nakamura, T | 1 |
| Abematsu, T | 1 |
| Nakagawa, S | 1 |
| Kodama, Y | 1 |
| Tanimoto, A | 1 |
| Okamoto, Y | 1 |
| Lauhan, CR | 1 |
| Schiff, D | 1 |
| Gloude, N | 1 |
| Martin, P | 1 |
| Yunon, MJ | 1 |
| Toh, SQ | 1 |
| Yan, SX | 1 |
| Chan, JY | 1 |
| Dholaria, B | 1 |
| Patel, RJ | 1 |
| Sluzevich, JC | 1 |
| Ailawadhi, S | 1 |
| Roy, V | 1 |
| Kwong, YL | 2 |
| Pang, AW | 1 |
| Leung, AY | 1 |
| Chim, CS | 1 |
| Tse, E | 1 |
| Khong, PL | 1 |
| Huang, B | 1 |
| Lee, EY | 1 |
| Chan, WK | 1 |
| Kim, TM | 1 |
| Kim, DW | 2 |
| Kang, YK | 1 |
| Chung, J | 1 |
| Song, HS | 1 |
| Kim, HJ | 1 |
| Kim, BS | 1 |
| Lee, JS | 1 |
| Kim, H | 1 |
| Yang, SH | 1 |
| Yuh, YJ | 1 |
| Bae, SH | 1 |
| Hyun, MS | 1 |
| Jeon, YK | 1 |
| Kim, CW | 1 |
| Heo, DS | 2 |
| Shao, Y | 1 |
| Guan, M | 1 |
| Chen, S | 1 |
| Jia, N | 1 |
| Wang, Y | 1 |
| Nagai, Y | 1 |
| Ikegame, K | 1 |
| Mori, M | 1 |
| Inoue, D | 1 |
| Kimura, T | 1 |
| Shimoji, S | 1 |
| Togami, K | 1 |
| Tabata, S | 1 |
| Kurata, M | 1 |
| Imai, Y | 1 |
| Matsushita, A | 1 |
| Nagai, K | 1 |
| Ogawa, H | 1 |
| Takahashi, T | 1 |
| Yamaguchi, M | 1 |
| Yau, YW | 1 |
| Tay, K | 1 |
| Koo, GC | 1 |
| Loong, S | 1 |
| Mottl, H | 1 |
| Bajciova, V | 1 |
| Nemec, J | 1 |
| Al Shemmari, S | 1 |
| Al Awadi, S | 1 |
| Park, BB | 1 |
| Kim, WS | 1 |
| Park, KW | 1 |
| Kang, JH | 1 |
| Lee, SH | 1 |
| Park, JO | 1 |
| Kim, K | 1 |
| Jung, CW | 1 |
| Park, YS | 1 |
| Im, YH | 1 |
| Kang, WK | 1 |
| Ko, YH | 1 |
| Lee, MH | 1 |
| Park, K | 1 |
| Fan, Y | 1 |
| Huang, ZY | 1 |
| Luo, LH | 1 |
| Yu, HF | 1 |
| Lee, KW | 1 |
| Yun, T | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Yoon, SS | 1 |
| Bang, YJ | 1 |
| Park, S | 1 |
| Kim, BK | 1 |
| Kim, NK | 1 |
| Bo, LJ | 1 |
| Liang, AB | 1 |
| Liu, B | 1 |
| Chen, YH | 1 |
| Wang, F | 1 |
| Jin, XP | 1 |
| Tanigawa, M | 1 |
| Ishiga, T | 1 |
| Ichioka, M | 1 |
| Saito, K | 1 |
| Reiter, A | 1 |
| Schrappe, M | 1 |
| Parwaresch, R | 1 |
| Henze, G | 1 |
| Müller-Weihrich, S | 1 |
| Sauter, S | 1 |
| Sykora, KW | 1 |
| Ludwig, WD | 1 |
| Gadner, H | 1 |
| Riehm, H | 1 |
| Pimentel, M | 1 |
| Johnston, JB | 1 |
| Allan, DR | 1 |
| Greenberg, H | 1 |
| Bernstein, CN | 1 |
| Orlandi, E | 1 |
| Lazzarino, M | 1 |
| Bernasconi, P | 1 |
| Astori, C | 1 |
| Bernasconi, C | 1 |
| Siegert, W | 1 |
| Agthe, A | 1 |
| Griesser, H | 1 |
| Schwerdtfeger, R | 1 |
| Brittinger, G | 1 |
| Engelhard, M | 1 |
| Kuse, R | 1 |
| Tiemann, M | 1 |
| Lennert, K | 1 |
| Huhn, D | 1 |
2 reviews available for ifosfamide and Lymphoma, T-Cell
| Article | Year |
|---|---|
[Concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Combined Moda | 2010 |
Primary adrenal lymphoma associated with adrenal insufficiency: a distinct clinical entity.
Topics: Addison Disease; Adrenal Cortex Neoplasms; Adrenal Gland Diseases; Adult; Antineoplastic Combined Ch | 1997 |
6 trials available for ifosfamide and Lymphoma, T-Cell
| Article | Year |
|---|---|
Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dexamethasone; Etoposide; Humans; Hydra | 2021 |
Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemother | 2014 |
A phase II study of ifosfamide, methotrexate, etoposide, and prednisolone for previously untreated stage I/II extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial of the Korean Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Femal | 2014 |
Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Disease-Free | 2015 |
Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymphoma; Child; Child, Preschoo | 1995 |
Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophos | 1992 |
14 other studies available for ifosfamide and Lymphoma, T-Cell
| Article | Year |
|---|---|
Treatment outcomes of T and natural-killer/T-cell lymphoma with ifosfamide, carboplatin and etoposide chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; Lymphoma | 2022 |
Systemic Epstein-Barr virus-positive T-cell lymphoma of childhood treated with the ICE regimen and allogeneic hematopoietic stem-cell transplantation.
Topics: Epstein-Barr Virus Infections; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans | 2023 |
Successful treatment of hepatosplenic T cell lymphoma in an adolescent with Turner syndrome using ifosfamide, carboplatin, and etoposide followed by allogeneic hematopoietic stem cell transplant.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; | 2020 |
Relapsed subcutaneous panniculitis-like T cell lymphoma: role of haploidentical hematopoietic stem cell transplant.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclo | 2017 |
Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparagi | 2014 |
Hepatosplenic alphabeta T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantation; Carbopla | 2010 |
A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Fem | 2011 |
High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Child, Presch | 2003 |
IMVP-16/Pd followed by high-dose chemotherapy and autologous stem cell transplantation as a salvage therapy for refractory or relapsed peripheral T-cell lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2005 |
[MINE regimen for patients with relapsed or chemo-resistant invasive non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Drug Resistance, Neo | 2005 |
First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2006 |
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[A case of CD56 positive T-cell lymphoma originating from mediastinal lymph nodes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; CD56 Antigen; Cyclophosphamide; Dexamet | 2006 |
Secondary acute myeloid leukemia following treatment with VP16-containing regimens for non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1998 |